Takeda Pharmaceutical/$TAK
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Takeda Pharmaceutical
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
- Ticker
- $TAK
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 47,029
- Headquarters
- Chuo, Japan
- Website
- www.takeda.com
TAK Metrics
BasicAdvanced
$67B
128.00
$0.16
0.10
$0.49
2.30%
Price and volume
Market cap
$67B
Beta
0.1
52-week high
$21.22
52-week low
$13.35
Average daily volume
2.8M
Dividend rate
$0.49
Financial strength
Current ratio
1.151
Quick ratio
0.51
Long term debt to equity
0.668
Total debt to equity
0.722
Dividend payout ratio (TTM)
773.83%
Interest coverage (TTM)
4.36%
Profitability
EBITDA (TTM)
8,093.764
Gross margin (TTM)
64.77%
Net profit margin (TTM)
0.87%
Operating margin (TTM)
14.65%
Effective tax rate (TTM)
1,760.19%
Revenue per employee (TTM)
$632,660
Management effectiveness
Return on assets (TTM)
2.89%
Return on equity (TTM)
0.56%
Valuation
Price to earnings (TTM)
128.001
Price to revenue (TTM)
1.113
Price to book
1.43
Price to tangible book (TTM)
-7.14
Price to free cash flow (TTM)
11.931
Free cash flow yield (TTM)
8.38%
Free cash flow per share (TTM)
1.753
Dividend yield (TTM)
2.35%
Forward dividend yield
2.30%
Growth
Revenue change (TTM)
6.25%
Earnings per share change (TTM)
24.96%
3-year revenue growth (CAGR)
4.15%
10-year revenue growth (CAGR)
10.34%
3-year earnings per share growth (CAGR)
-40.38%
10-year earnings per share growth (CAGR)
-18.17%
3-year dividend per share growth (CAGR)
3.16%
10-year dividend per share growth (CAGR)
1.16%
What the Analysts think about TAK
Analyst ratings (Buy, Hold, Sell) for Takeda Pharmaceutical stock.
Analyst projections of the future price of Takeda Pharmaceutical stock.
Bulls say / Bears say
Takeda has moved several prospective growth drivers closer to patients: ORZEYFUL is approved in the US, Japan and China, MIMRYLO has launched in the US, and zasocitinib is under priority review. Successful launches could help replace sales lost from older products. (Takeda Pharmaceuticals)
Arcotatug tavatecan met both primary endpoints in a Phase 3 gastric-cancer trial, extending median overall survival to 10.2 months from 6.9 months. The result supports a planned Japan filing and offers Takeda a promising oncology growth opportunity if approved. (Takeda Pharmaceuticals)
A Phase 4 study found that treating ulcerative-colitis patients with ENTYVIO towards disease clearance reduced the risk of related complications by nearly 70%. This evidence could help reinforce the position of an established brand in a competitive market. (Takeda Pharmaceuticals)
Core revenue fell 1.0% at constant exchange rates in the first half, and full-year guidance still points to a low-single-digit core revenue decline and a low-teens core EPS decline. The stronger reported outlook largely reflects foreign-exchange benefits rather than underlying growth. (Takeda Pharmaceuticals)
After a US jury verdict in the AMITIZA antitrust case, Takeda booked a ¥402.5 billion provision and said the final liability remains unsettled. Its planned appeal leaves a material legal and potential cash-flow overhang. (Takeda Pharmaceuticals)
Generic erosion is already hurting VYVANSE, while TRINTELLIX faces expected US generic competition after December 2026 and ENTYVIO will lose regulatory exclusivity later this decade. These pressures could make it harder for new launches to sustain revenue and earnings. (Takeda Pharmaceuticals, StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
TAK Financial Performance
Revenues and expenses
Upcoming events
No upcoming events
TAK News
AllArticlesVideos
What Takeda Pharmaceutical (TAK) Said on Its Q2 Earnings Call
MarketBeat3 days ago
Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
Business Wire4 days ago
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study
Business Wire1 week ago
Funds containing TAK
AllUSDEUR
Fund name | Fund size | $TAK weighting |
|---|---|---|
JPMorgan Global Equity Premium Income£JEGP | $1.6B | 1.63% |
JPMorgan Global Equity Premium Income$JEPG | $1.5B | 1.63% |
Xtrackers MSCI World Health Care$XDWH | $4.1B | 0.72% |
Xtrackers MSCI World Health Care£XWHS | $4.1B | 0.72% |
SPDR MSCI World Health Care$WHEA | $708M | 0.72% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.